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Clinics and pathology 
Phenotype/cell stem origin 
Light chain restriction surface immunoglobulin. Most 
cases express IgM and IgD. B-cells express CD19+, 
CD20+, CD22+, CD24+, CD79b+, FMC7+ and 
DBA44+. Lack expression of CD5 (85%), CD10, 
CD23, CD103 and CD123. 
Epidemiology 
In 1987, the term SLVL was introduced; 1-2% of non-
Hodgkin lymphomas; occurs in the elderly (med 70 
yrs); sex ratio 2M/1F. 
Clinics 
Splenomegaly without hepatomegaly nor enlarged  
 
lymph nodes; monoclonal Ig in a third of cases,  
autoimmune phenomena in 10% of patients, 
transformation to high grade lymphoma in 10% of 
cases. 
Pathology 
Spleen. Nodular replacement of the white pulp with a 
central core of small lymphocytes and larger cells in 
the peripheral marginal zone. Invasion of the splenic 
red pulp is inconstant. Bone marrow morphology 
showing intrasinusoidal lymphoma cells. 
Treatment 
Only in symptomatic patients: splenectomy or 
chemotherapy with purine analogues. Antiviral therapy 
(IFN) in patients with SLVL and hepatitis C. 
 
 
Peripheral blood lymphocytosis in 75% of patients and villous lymphocytes on peripheral blood smears (Fig 1). 














Indolent B-cell malignancy with 5-yr survival: 80%; no 
consensus on adverse prognostic factors: WBC > 30 x
109/l, low lymphocyte count; cases treated with 
chemotherapy have shorter survival. 
Cytogenetics 
Cytogenetics morphological 
A low mitotic activity is present in SLVL and most 
chromosomal banding analyses of SLVL have been 
based on cell cultures stimulated with different B-cell 
mitogens. The cytogenetic abnormalities are 
heterogeneous and often complex, with several 
recurrent abnormalities. 
The most common abnormalities are those involving 
structural abnormalities of chromosome 7q22-q32 [20-
40% of cases] in the form of translocation, mainly 
unbalanced, and 7q deletion (see Fig 2). 
Some cases have been reported to show 
t(11;14)(q13;q32) [10-15%]. 
Structural abnormalities and microdeletion of 13q14 
were found in 50% of cases. The 13q14 allelic losses at 
the RB1 locus deletion have been detected by 
interphase FISH. 
Other abnormalities, in particular trisomy 3 [10-15%], 
i(17)(q10), t(6;14)(p21;q32) and 2p11 translocations, 
t(2;7)(p12;q21) were also observed in a few cases. 
Immunoglobulin gene sequencing 43% of patients have 
an unmutated profile (>98% homology to the gem line 
sequence) and 57% of patients a mutated profile. 
Overuse of the VH1-2 gene segment is present in 
mutated and unmutaded cases. 
 
Genes involved and proteins 
Note 
del(7q): gene unknown. 
t(11;14)(q13;q32)BCL1 in 11q13 and IgH in 14q32 are
involved in 20% of cases, with or without visible 
(11;14); BCL1 encodes the cyclin D1; role in the cell 
cycle control (G1 progression and G1/S transition); 5' 
BCL1 translocated on chromosome 14 near JH, 
resulting in promoter exchange; the immunoglobulin 
gene enhancer stimulates the expression of BCL1, and 
overexpression of BCL1 which accelerates passage 
through the G1 phase. 
Trisomy 3: gene unknown but region 3q13.q32-q29 
over-represented. 
t(6;14)(p21;q32) cyclin D3 is located on 6p21 and, as 
CDK6, is implicated in the progression through the G1 
phase of the cell cycle. 
t(2;7)(p12;q21). CDK6 is located on 7q21 and 
dysregulation of CDK6 gene expression could be 
contribute to the pathogenesis of SLVL and SMZL. 
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